Search

In patients with resected pancreatic ductal adenocarcinoma, alterations in KRAS and TP53 were associated with worse outcomes, whereas alterations in homologous recombination deficiency genes were associated with favorable prognoses.

… Thursday, July 16, 2020 In patients with resected pancreatic ductal adenocarcinoma (PDAC), alterations in KRAS and TP53 were associated with worse outcomes, whereas alterations in homologous recombination deficiency (HRD) genes were associated with favorable prognoses, according to a study by our research

A new Memorial Sloan Kettering study has identified one of the proteins fueling the spread of some breast cancers, and researchers hope their findings will lead to the development of new diagnostic tools and drugs.

… Friday, August 24, 2012 Summary A new Memorial Sloan Kettering study has identified one of the proteins fueling the spread of some breast cancers, and researchers hope their findings will lead to the development of new diagnostic tools and drugs. Cancer experts have long known that virtually all cancers

A Q&A with MSK Urologic Surgeon Richard Matulewicz, MD, MSCI, MS.

… Monday, September 9, 2024 Since 2013, MSK has offered primary retroperitoneal lymph node dissection (RPLND) to select patients with low-volume incident or relapsed seminoma metastatic only to the retroperitoneum, in lieu of the traditional standards of care which were previously chemotherapy or radiation

Hear from Memorial Sloan Kettering breast surgical oncologist Tracy-Ann Moo about her experience as a woman of color in medicine.

… Wednesday, February 10, 2021 In honor of Black History Month, we spoke with Memorial Sloan Kettering breast surgical oncologist Tracy-Ann Moo about the challenges of being a person of color in medicine — especially in the age of COVID-19. The most recent data from the Association of American Medical

Investigators at MSK are developing new immunotherapy treatments that rely on engineering T cells to recognize mutated proteins that are unique to cancer.

… Friday, April 29, 2022 Immunotherapy is an increasingly important form of cancer treatment. It encompasses a class of cancer therapies that harness the immune system’s natural ability to recognize and eliminate tumor cells. Most immunotherapies work by boosting the power of a type of white blood cell

Learn how MSK researchers are investigating the use of nanoparticles to carry drugs across the blood-brain barrier.

… Thursday, March 2, 2023 The blood-brain barrier prevents most drugs from reaching brain tumors. A new method using nanoparticles transported drugs across this barrier in mice. The nanoparticles target a protein on tumor blood vessel cells called P-selectin. The nanoparticles improved the treatment in

Scientists and scholars received degrees and awards at MSK's 40th annual ceremony, held on May 29.

… Friday, May 31, 2019 The GSK class of 2019 The newly minted graduates look on during the ceremony. Craig Thompson, President and CEO of MSK Craig Thompson, President and CEO of MSK, applauds the bright young minds at the 2019 Convocation and Commencement of the Gerstner Sloan Kettering Graduate School

Learn how the Pediatric Translational Medicine Program at Memorial Sloan Kettering is bringing together experts to make new discoveries about pediatric cancer.

… Wednesday, March 6, 2019 Summary A new program at MSK seeks to further harness the power of collaboration to give children innovative treatments, which will in turn help other kids down the line. At MSK Kids, our team of experts puts caring for children and their families in the center of all we do.

The in-person event featured scientific talks from leading women in science, including winners of this year’s Kravis WISE fellowships.

… Thursday, April 14, 2022 Three women standing next to each other in a lobby Marie-Josée Kravis (middle) with 2022 Kravis WiSE fellowship winners Xiuzhen Chen (left) and Brianna Naizir (right) A female scientist speaking at a podium Erika Pearce, PhD, Bloomberg Distinguished Professor at the Johns Hopkins

The incidence of mouth and throat cancer is on the rise due to oral transmission of the human papilloma virus, but the "silver lining" of this phenomenon is doctors at Memorial Sloan Kettering have significantly reduced the intensity of treatment while achieving excellent outcomes for these patients.

… Wednesday, February 15, 2017 The incidence of mouth and throat cancer is on the rise due to transmission of the human papilloma virus (HPV), but the “silver lining” of this phenomenon is doctors at Memorial Sloan Kettering (MSK) can significantly reduce the intensity of treatment and improve quality